Genetic Variants and Soluble Isoforms of PD-1/PD-L1 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma (PDAC) Susceptibility and Prognosis

Bibliographic Information
Authors: Hassan M.; El-Maadawy W.H.; Elhusseny Y.; Agamy F.E.; Fahim S.A.; Balata M.
Journal: Biomedicines
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
Publication Date: 12 September 2025
Volume / Issue: Volume 13 / Issue 9
Article No.: 2246
ISSN: 22279059
DOI: 10.3390/biomedicines13092246
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Hassan M., Immunology Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt; El-Maadawy W.H., Pharmacology Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Elhusseny Y., Medical Biochemistry and Molecular Biology Department, School of Medicine, NewGiza University, Giza, 12585, Egypt; Agamy F.E., Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt; Fahim S.A., Biochemistry Department, School of Pharmacy, NewGiza University, Giza, 94114, Egypt; Balata M., University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany, University Hospital Rostock, Ernst-Heydemann-Straße 6, Rostock, 18057, Germany
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive neoplasm often diagnosed at advanced stages. Immune checkpoint molecules, particularly programmed cell death protein-1 (PD-1) and its ligand PD-L1, are pivotal in tumor immune evasion. Genetic polymorphisms in PD-1/PD-L1 and their soluble isoforms (sPD-1/sPD-L1) may influence individual susceptibility to cancer and disease progression. Therefore, this study was conducted to examine the correlation between PD-1/PD-L1 gene polymorphisms, serum levels of sPD-1/sPD-L1, and their association with PDAC susceptibility, severity, and prognostication. Methods: This case–control study was performed with 150 PDAC patients and 150 controls. Clinical and laboratory data, including tumor markers (CA19-9 and CEA), were recorded. Allele-specific PCR was utilized to genotype PD-1 (rs6749527 and rs7421861) and PD-L1 (rs2297136, and rs4143815). sPD-1/sPD-L1 were quantified with ELISA. Mapping of the Kaplan–Meier survival curve of mutant genes was performed. Results: The rs7421861 AG and GG and rs4143815 GG genotypes, together with their G-alleles, were linked to increased PDAC risk and greater tumor burden. In contrast, the rs2297136 GG genotype and G-allele conferred protection against PDAC development. Serum sPD-L1 levels, rather than sPD-1, were markedly elevated in PDAC patients, progressively increased with tumor grade, and correlated with tumor markers. Also, higher PD-L1 gene expression was associated with lower overall survival. Conclusions: PD-1/PD-L1 genetic variants, particularly rs7421861 and rs4143815, along with sPD-L1 levels, correlate with PDAC susceptibility and disease severity. These findings endorse the prospects of integrating immune checkpoint genetic variants and soluble biomarkers for early identification, risk stratification, prognostication, and personalized therapeutic strategies in PDAC management. © 2025 by the authors.
Keywords
immune checkpoint; pancreatic ductal adenocarcinoma; PD-1; PD-L1; rs4143815; rs7421861; single nucleotide polymorphism; alanine aminotransferase; albumin; aspartate aminotransferase; bilirubin; biological marker; creatinine; genomic DNA; immune checkpoint inhibitor; immune checkpoint protein; programmed death 1 ligand 1; programmed death 1 receptor; tumor necrosis factor; urea; adult; allele; Article; blood sampling; cancer chemotherapy; cancer immunotherapy; cancer patient; cancer prognosis; cancer radiotherapy; cancer staging; cancer susceptibility; case control study; CD8+ T lymphocyte; cell death; clinical outcome; cohort analysis; computer assisted tomography; controlled study; female; genetic polymorphism; genetic variability; genotype; human; immune evasion; immune response; major clinical study; male; middle aged; nuclear magnetic resonance imaging; overall survival; pancreas cancer; pancreatic ductal carcinoma; protein protein interaction; smoking
Citation Information
Scopus Citations: 5
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
